The impact of second-line chemotherapy on advanced pancreatic cancer: A retrospective study in Reggio Emilia Clinical Cancer Centre.

被引：0
|
作者：
Baldi, Licia
Panebianco, Michele
Rossi, Paolo Giorgi
Mancuso, Pamela
Cassetti, Tiziana
Sassatelli, Romano
Pinto, Carmine
机构：
[1] Arcispedale Santa Maria Nuova IRCCS, Med Oncol Unit, Ctr Clin Canc, Reggio Emilia, Italy
[2] IRCCS Arcispedale S Maria Nuova, Inter Inst Epidemiol Unit, Reggio Emilia, Italy
[3] IRCCS Arcispedale S Maria Nuova, Gastroenterol & Endoscopy Dept, Reggio Emilia, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15732
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15732
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Second-line chemotherapy for patients with advanced gastric cancer
    Takahari, Daisuke
    GASTRIC CANCER, 2017, 20 (03) : 395 - 406
  • [32] Clinical predictors of second-line chemotherapy (ChT) benefit in pancreatic cancer (PC).
    Pokataev, Ilya
    Bazin, Igor
    Fedyanin, Mikhail
    Tryakin, Alexey
    Popova, Anna
    Rumyantsev, Alexey
    Sekhina, Olga
    Patutko, Yury
    Fainstein, Igor
    Tjulandin, Sergei
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis
    Dakik, Hassan K.
    Moskovic, Daniel J.
    Carlson, Peter J.
    Tamm, Eric P.
    Qiao, Wei
    Wolff, Robert A.
    Abbruzzese, James L.
    Fogelman, David R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) : 425 - 430
  • [34] The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis
    Hassan K. Dakik
    Daniel J. Moskovic
    Peter J. Carlson
    Eric P. Tamm
    Wei Qiao
    Robert A. Wolff
    James L. Abbruzzese
    David R. Fogelman
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 425 - 430
  • [35] The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer
    Boeck, Stefan
    Heinemann, Volker
    FUTURE ONCOLOGY, 2008, 4 (01) : 41 - 50
  • [36] A clinical study of docetaxel with or without 5'DFUR as a second-line chemotherapy for advanced gastric cancer
    Maruta, Fukuto
    Ishizone, Satoshi
    Hiraguri, Manabu
    Fujimori, Yoshiro
    Shimizu, Fumiaki
    Kumeda, Shigeyoshi
    Miyagawa, Shinichi
    MEDICAL ONCOLOGY, 2007, 24 (01) : 71 - 75
  • [37] Second-line palliative chemotherapy, survival, and prognostic factors in patients with advanced pancreatic cancer
    Ekstrom, Anders
    Brun, Eva
    Eberhard, Jakob
    Segerlantz, Mikael
    ACTA ONCOLOGICA, 2021, 60 (12) : 1580 - 1588
  • [38] A clinical study of docetaxel with or without 5′DFUR as a second-line chemotherapy for advanced gastric cancer
    Fukuto Maruta
    Satoshi Ishizone
    Manabu Hiraguri
    Yoshiro Fujimori
    Fumiaki Shimizu
    Shigeyoshi Kumeda
    Shinichi Miyagawa
    Medical Oncology, 2007, 24 : 71 - 75
  • [39] Second-line chemotherapy in advanced gastric cancer: A retrospective, single-center analysis
    Herrmann, C.
    Jaeger, D.
    Herrmann, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study.
    Walter, Thomas
    Horgan, Anne
    McNamara, Mairead Geraldine
    McKeever, Elizabeth
    Min, Trisha
    Hedley, David W.
    Serra, Stefano
    Krzyzanowska, Monika K.
    Chen, Eric Xueyu
    Mackay, Helen
    Feld, Ronald
    Moore, Malcolm J.
    Knox, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345